Lower dose alemtuzumab for kidney transplant rejection
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a reduced dose of alemtuzumab, a medicine that calms the immune system, for people whose kidney transplant is being rejected and standard treatments haven't worked or aren't safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are being treated for severe kidney transplant rejection or rejection that doesn't respond to standard steroid treatments
- You will be treated with alemtuzumab for this rejection
- You have not received a different immune-suppressing drug (like rATG) for this same rejection episode
- Your T cell count is not too low (above 200 × 10⁶/L) before starting alemtuzumab
- You are able to give written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This trial tests a medication called belatacept to see if it can prevent or treat early antibody-mediated rejection in kidney transplant recipients who have developed new donor-specific antibodies but still have stable kidney function.
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
This trial compares a new drug called frexalimab to the standard drug tacrolimus in people who are getting their first kidney transplant. The goal is to see if frexalimab works better and has a safer side effect profile.
This Phase 2 study looks at the best dose of alemtuzumab (a medicine used before transplant) for children undergoing a donor stem cell transplant for a non-cancer illness. It may help doctors fine-tune dosing to improve how the drug behaves in the body and make future transplant care more precise.
This trial tests a new approach to treat T-cell mediated rejection in kidney transplant recipients. It aims to safely and effectively stop the rejection episode.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.